Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity Results of a multicentre pilot study;Trattamento combinato acido butirrico/mesalazina nella rettocolite ulcerosa in attività lieve-moderata

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 3, 2008, Pages 231-238

  Assisi, R F ^a,s   Assisi, R ^b   De Stefano, S ^b   Pezzullo, A ^c   Ciacci, C ^d   Luisi, T ^e   Claar, G M ^f   Guardascione, F ^g   Amato, G ^d   Curro ^h   Bayeli, P ⁱ   Monastra, S ^j   Cattaneo, D ^k   Montanaro, F ^l   Ricco, G ^m   Gasbarrini, G ⁿ   Guglielmo, S ^o   Di Benedetto, M ^p   Barletta, G ^d   Napoletano, V ^q   Casale, V ^r   Assisi, D ^r   Di Todaro, E ^s   more..

^a S Maria delle Grazie Hospital   (Italy)

^b UO di Gastroenterologia ed Endoscopia Digestiva

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Ambulatorio di Gastroenterologia   (Italy)

^f San Giuseppe Moscati Hospital   (Italy)

^g Ospedale di Giugliano in Campania

^h Clinica Candela   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

^j San Gennaro Hospital   (Italy)

^k MONALDI HOSPITAL   (Italy)

^l Ospedale San Giovanni di Dio   (Italy)

^m Casa di Cura Villa del Sole   (Italy)

ⁿ CATHOLIC UNIVERSITY   (Italy)

^o Ospedale GF Ingrassia   (Italy)

^p Casa di Cura San Michele   (Italy)

^q REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^r Ospedale Civile di Massafra

^s S Maria delle Grazie Hospital   (Italy)

more..

Author keywords

Butyric acid; Colitis, ulcerative; Fatty acids, volatile; Probiotics

Indexed keywords

ANTIINFLAMMATORY AGENT; BUTYRIC ACID PLUS INULIN; MESALAZINE; UNCLASSIFIED DRUG; ZACOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA; MULTICENTER STUDY; PILOT STUDY; RECURRENT DISEASE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTYRIC ACID; COLITIS, ULCERATIVE; DRUG COMBINATIONS; FEMALE; GASTROINTESTINAL AGENTS; HISTAMINE ANTAGONISTS; HUMANS; INTESTINAL MUCOSA; INULIN; ITALY; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; TABLETS; TREATMENT OUTCOME;

EID: 57449084031     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mortensen PB, Clausen MR. Short-Chain Fatty Acid in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996;216:132-482.
2. Wächtershäuser A, Stein J. Rationale for the luminal provision of butyrate in intestinal disease. Eur J Nutr 2000;39:164-71.
3. Velazquez OC et al. Butyrate and the coloncyte. Dietary fiber in healt and Disease. In: Vahouny GV, Kritchevsky D, editors. New York: Plenum Press; 1977. p. 123-34.
4. Weaver GA, Tangel CT, Krause JA, Parfitt MM, Stragand JJ, Jenkins PI, et al. Biomarkers of human colonic cell growth are influenced differently by a history of colonic neoplasia and the consumption of acarbose. J Nutr 2000;130:2718-25.
5. Bradburn DM, Mathers JC, Gunn A, Burn J, Chapman PD, Johnston ID. Colonic fermentation of complex carbohydrates in patients with familial adenomatous polyposis. Gut 1993;34:630-6.
6. D'Argenio G, Mazzacca G. Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer. Adv Exp Med Biol 1999;472:149-58.
7. Finnie IA, Dwarakanath AD, Taylor BA, Rhodes JM. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995;36:93-9.
8. Rodríguez-Cabezas ME, Gálvez J, Lorente MD, Concha A, Camuesco D, Azzouz S et al. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr 2002;132:3263-71.
9. Klampfer L, Huang J, Sasazuki T, Shimsawa S, Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res 2003;1:855-62.
10. Menzel T, Lührs H, Zirlik S, Schauber J, Kudlich T, Gerke T et al. Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm Bowel Dis 2004;10:122-8.
11. Kobayashi H, Tan EM, Fleming SE. Sodium butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells independently of p53 status. Nutr Cancer 2003;46:202-11.
12. Orchel A, Dzierzewicz Z, Parfiniewicz B, Weglarz L, Wilczok T. Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig Dis Sci 2005;50:490-8.
13. Ruemmele FM, Schwartz S, Seidman EG, Dionne S, Levy E, Lentze MJ. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut 2003;52:94-100.
14. Vernia P, Marcheggiano A, Caprilli R, Frieri G, Corrao G, Valpiani D. Short chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:309-13.
15. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis. Dig Dis Sci 2000;45:976-81.
16. Scheppach W. Treatment of distal ulcerative colitis with short chain fatty acid enemas. A placebo controlled trial. Dig Dis Sci 1996;41:2254-9.